Literature DB >> 1088073

Alfa-antitrypsin increase in lung cancer.

G Daddi, P A Mancini, D Parola, A Contini.   

Abstract

The Authors controlled the content of A1AT in the sera of 100 patients with L.Ca. As controls there were examined: 20 cases of metastatic neoplasm of the lung, 5 cases of systemic sarcomatosis, 10 cases of acute bacterial bronchopneumonia, 4 cases of bronchiectasis and emphysema. Moreover, the levels of A1AT was studied in 15 pl.fl., neoplastic and not, in comparison with the levels of the sera. None of the controls demonstrated an increase in A1AT, excepting the cases of acute bronchopneumonia, in which the levels were very high but only for a few days. The results indicate that in more than 90% of the L.Ca. the level of the A1AT is significantly higher than in the sera of the controls, with possible variations during the disease. There is a clear trend towards increase parallel with the worsening of the condition of the patients. A course of chemotherapy may bring down the levels, proportionally to the length and intensity of the treatment. After discontinuance, the level increases again more or less quickly, reaching the previous values.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1088073

Source DB:  PubMed          Journal:  Boll Ist Sieroter Milan        ISSN: 0021-2547


  2 in total

1.  Alpha1-antitrypsin deficiency carriers, serum alpha 1-antitrypsin concentration, and non-small cell lung cancer survival.

Authors:  Yan Li; Michael J Krowka; Yingwei Qi; Jerry A Katzmann; Yong Song; Yafei Li; Sumithra J Mandrekar; Ping Yang
Journal:  J Thorac Oncol       Date:  2011-02       Impact factor: 15.609

2.  Clinical Significance of SERPINA1 Gene and Its Encoded Alpha1-antitrypsin Protein in NSCLC.

Authors:  Evrim Ercetin; Sarah Richtmann; Beatriz Martinez Delgado; Gema Gomez-Mariano; Sabine Wrenger; Elena Korenbaum; Bin Liu; David DeLuca; Mark P Kühnel; Danny Jonigk; Kadriya Yuskaeva; Arne Warth; Thomas Muley; Hauke Winter; Michael Meister; Tobias Welte; Sabina Janciauskiene; Marc A Schneider
Journal:  Cancers (Basel)       Date:  2019-09-04       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.